GLENMARK Glenmark Pharmaceuticals Q1 FY26 results (Apr–Jun 2025) and concall
Glenmark Pharma reported a modest 0.6% Y-o-Y consolidated revenue growth in Q1 FY26, reaching INR 32,644 million. While India's formulation business and Consumer Care showed strong growth, Europe and Emerging Markets faced headwinds. The company settled a US antitrust litigation for USD 37.75 million and expects EBITDA margins to stabilize at 23%+ from Q3 FY26, driven by a strategic shift towards high-margin branded products and new launches.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 2,636 | 2,251 | 2,010 | 2,395 |
| EBITDA | 779 | 494 | 341 | 728 |
| Net profit | 595 | 414 | 148 | 330 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
